Clinical Trials Logo

Immunoglobulin A Nephropathy clinical trials

View clinical trials related to Immunoglobulin A Nephropathy.

Filter by:

NCT ID: NCT02605525 Withdrawn - Clinical trials for Immunoglobulin A Nephropathy

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

Start date: December 31, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of SM101 in the treatment of Immunoglobulin A nephropathy (IgAN)

NCT ID: NCT02384317 Completed - Clinical trials for Immunoglobulin A Nephropathy

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

Start date: March 27, 2015
Phase: Phase 2
Study type: Interventional

The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in proteinuria.

NCT ID: NCT01838239 Completed - Healthy Subjects Clinical Trials

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN) and in healthy subjects. The hypothesis is that measuring variation among individuals and changes in response to omega-3 fatty acids comprehensively by using metabolomics will help to identify those individuals who are responders and those who are non-responders to omega-3 fatty acids as an anti-inflammatory intervention.